Recent

% | $
Quotes you view appear here for quick access.

MultiCell Technologies, Inc. Message Board

  • sfsi_mont sfsi_mont Jul 4, 2013 12:59 PM Flag

    maxxi7 . . i got the exact same email from Barbara

    from Barbara
    word for word.

    maxxi7 . . i got the exact same email from Barbara
    word for word.

    here are my thoughts about that email;

    . . so now we know that Dr. Zaghouani was working on chimeric immunoglobulin,
    chimeric immunoglobulin, are T-cell receptors (cIgTCRs).

    in the MCT-475 description on MCET website they state in the second paragraph:

    "The uniqueness of the ETI platform is related to its novel "epitope delivery" vehicle, namely chimeric recombinant immunoglobulin G (IgG) molecules that carry the epitope sequence . ..

    MCT-475 may be the step up from mct-275.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I saw a report and MCT-275 is owned by MCET. If this drug has this value, we should see a PR and an increase in the stock value.

      Sentiment: Strong Buy

      • 1 Reply to tal657
      • . .here's an email response from Barbra to me

        In response to your question about the status of MCT-275

        MCT-275 was based on technology developed by Dr. Zaghouani and exclusively licensed to Astral, Inc. (subsequently acquired by MultiCell). In 2008 Dr. Zaghouani published a research article where he found that contrary to his original 1997 publication, a proteolipid protein (PLP) antagonist peptide presented in a chimeric immunoglobulin format not only failed to ameliorate but actually aggravated the autoantibody response in animal models of multiple sclerosis. Based on these findings by Dr. Zaghouani, MultiCell ceased any further development of a chimeric immunoglobulin based on Dr. Zaghouani's technology.

        Barbara Corbett, Investor Relations,

 
MCET
0.00020.0000(0.00%)Jun 24 1:06 PMEDT